Quanta Capital Holdings Ltd (QNTA) – Globe Newswire
-
Quanta and Medolife Rx Provide Updates on Activities and Plans
-
Medolife Rx in Discussions with a Major Infomercial Agency and Receives Exceptionally Positive Product Reviews
-
Medolife Rx Schedules Conference Call with Investment Community to Discuss New Updates and Answer Questions
-
Medolife Rx Announces Changes to Management and Improvements to AELIA’s Marketing Efforts
-
Medolife Rx Submits Final Clinical Trial Data for Escozine Approval as a COVID-19 Treatment in The Dominican Republic
-
Medolife Rx Presents Its Venom-To-Drug Development Projects at an International Conference Held in the Dominican Republic
-
Medolife Rx Announces Results of Comparative Study of Its Flagship CBD-based Muscle Rub and Competitor Products
-
Medolife Rx Schedules Conference Call with Investment Community To Discuss Third Quarter 2021 Financial and Operational Results and New Updates
-
Medolife Rx Announces Upcoming Release of New Aelia Commercials Featuring Tony Hawk
-
Medolife Rx Announces Uplisting to OTCQB Venture Market
-
Medolife Rx Announces that the Government of the Dominican Republic is Willing to Include Escozine into its COVID-19 Treatment Regimen
-
Medolife Rx Reports 257% Increase in Efficacy of Ibuprofen Through Proprietary Polarization Method, Looks to Expand Into Other APIs
-
Medolife Rx Initiates Comparative Study of Its Flagship CBD-based Muscle Rub and Competitor
-
Medolife Rx Files Bi-Annual Report With Ministry of Environment in the Dominican Republic, Details Reservation Expansion and Exceeds Regulatory Expectations
-
Medolife Rx Launches Ad Campaign With Tony Hawk, Sees Immediate Positive Results
-
Medolife Rx Clarifies April 13, 2021 Press Release
-
Medolife Rx Completes Bi-Annual Visit From Ministry of Environment to Scorpion Reservation, Receives Positive Feedback and Re-Affirmation of Joint Venture
-
Medolife Rx Recaps Successful Attendance at Tony Hawk Event; Saw Significant Product Exposure
-
Medolife Rx Reports Second Quarter 2021 Financial and Operational Results, Schedules Conference Call With Investment Community
-
Medolife Rx to Participate in Inaugural Tony Hawk’s Vert Alert, Showcasing Breakthrough Pain Relief and Immunapen Product Lines
-
Medolife Rx Launches Pharmacokinetic Study on Lead Drug Candidate as Next Step in Pre-IND FDA Submission
-
Medolife Rx Cancels Optional Reverse Split Previously Included in Filing
-
Medolife Rx Schedules Investor Webcast for Tuesday, July 27, 2021
-
Medolife Rx Announces Donation of Escozine to Heath Clinic in Dominican Republic for Use on Growing COVID-19 Positive Patient Population
-
Medolife Rx Clinical Observations Demonstrates Effectiveness of Escozine in Complementary Use with COVID-19 Vaccines
-
Medolife Rx Announces Successful Stability Results on Escozine Conjugated With Radioactive Iodine
-
Medolife Rx Enters Partnership Agreement with Leading International Distributor, Brings Products to Mexico
-
FDA Accepts COVID-19 Clinical Study and Advises on Next Steps for Pre-IND Filing by Medolife Rx
-
Medolife Rx Signs Product Endorsement Agreement With Legendary Skateboarder Tony Hawk
-
Medolife Rx Provides Comment on Business in Lieu of Webcast Scheduled for June 8, 2021
-
Medolife Rx Schedules Investor Webcast for Tuesday June 8, 2021
-
Medolife Rx Launches National TV PSA Campaign Promoting Escozine and Activates Customer Service Center
-
Medolife Rx Successfully Produces Medical Batch of Escozine Through In-house Facilities, Ready for Submission to DR Ministry of Health for Further Trials
-
Medolife Rx Reports First Quarter 2021 Financial and Operational Results, Schedules Conference Call with Investment Community
-
Medolife Rx Completes Initial Meeting with Bioethics Committee, Preparing for Commencement of Phase II Clinical Trial on Lead Drug Candidate
-
Medolife Rx CEO Receives Achievement Award From Regulatory Agency in the Dominican Republic for Work on COVID-19 Treatment
-
Medolife Rx Announces New Extraction Facility and Scientific Team in Place
-
Medolife Rx Announces Changes in Management, Puts New Executive Leadership in Place
-
Medolife Rx Implements Proprietary Electro Solution, Further Increasing Efficacy of Polarization Technology
-
Medolife Rx Announces Historic Product Registration in Dominican Republic Enabling Escozine to Be Sold Throughout Latin America as Natural Alternative Cancer Medicine
-
Medolife Rx Breaks Ground on Lab Facility and Increases Scorpion Count at First-of-Its-Kind Reservation in the Dominican Republic
-
Medolife Rx Announces Pre-Clinical Results on Escozine Showing Synergistic Effect in Killing Cancer Cells When Combined With Chemotherapy Agents
-
Medolife Rx (Quanta, Inc.) Reports Over $1 Million in Revenue in 2020 Year-End Filing, Comments on Operations
-
Medolife Rx to Present at The 2021 Sequire Cannabis Conference on Tuesday, April 20, at 3 p.m. EST/12 p.m. PST
-
Medolife Rx Submits Final Data Set to FDA for IND Filing on Lead Drug Candidate
-
Medolife Rx Announces Positive Pre-Clinical Results Showing Up to 95 Percent Cancer Cell Apoptosis with Introduction of Lead Cancer Drug Candidate
-
Medolife Rx Receives Significant Purchase Order of Immunapen, Its Easy-to-Use Nutraceutical Product Designed to Increase Quality of Life and Support a Healthy Immune System
-
Medolife Rx’s Lead Drug Candidate Escozine® Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic
-
Medolife Rx Furthers Expansion of Scorpion Reservation; Prepares for Mass Production of Escozine Required Upon Product Registration
-
Medolife Rx Completes Batch Production of Escozine® for FDA Submission
Back to QNTA Stock Lookup
